← All trials
NCT05156658
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 25, 2022
- Primary completion
- Feb 25, 2024
- Completion date
- Feb 25, 2024
- First posted
- Dec 14, 2021
- Last posted
- Dec 14, 2021
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- AIDS Clinical Trials GroupLead sponsor
- University of ColoradoStudy chair
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.